MEDIA ALERT: Eularis to Address Marketing Return at Measuring Marketing ROI in
Pharma Conference in London
NEW YORK and LONDON, March 10 /PRNewswire/ -- Dr. Andree Bates, president
of the pharmaceutical analytics company Eularis, will be delivering a
presentation on meeting the challenges of measuring ROI within the changing
dynamics of the pharma industry.
*(LOGO 72dpi: Send2Press.com/mediaboom/07-0924-Eularis_72dpi.jpg)
On Wednesday 26 March 2008, Dr. Bates will deliver a presentation titled,
"Are You Up to the Challenge of Measuring ROI in Changing Dynamics of the
Pharma Industry?" Bates will challenge the thinking of conference attendees
and will expose where ROI goes wrong when used to guide current marketing
decisions in a changing dynamic market such as pharma. She will also uncover
what opportunities are available in this environment, and what can and should
be measured for real results when the environment is dynamic.
Bates has gained wide recognition within the international pharmaceutical
industry for her expertise in marketing return analysis. Under Bates'
leadership, Eularis issued three related research reports in the past year,
including: Ensuring Profitable Return-on-Investment (ROI) in Pharmaceutical
Marketing: Using Analytics and Metrics to Improve the Bottom Line
(http://www.pharmamarketingroi.com), Pharmaceutical Sales Force Effectiveness
Metrics: Are You Measuring the Wrong Things?
(http://www.pharmaindustrysfe.com), and Ensuring Profitable Patient Adherence
Programs by Effectively Using Analytics to Release the Hidden Value Available
to the Bottom Line from Adherence (http://www.patientadherenceroi.com).
The conference will be focused on answering three pivotal areas:
"Addressing the Challenges in Measuring ROI," "Ensuring the Sales and
Marketing Functions are Aligned" and "Leveraging Your Brand Potential."
To arrange an interview with Eularis http://www.eularis.com, please
contact Tracey Haefele at +1 646 673 8408 or via email THaefele@Eularis.com.
About Eularis
Eularis provides sophisticated pharmaceutical analytics that provide
data-driven insight into the financial impact of corporate and marketing
decisions. Eularis' proprietary 94.8 Analytics Process is based on the
current market situation. This proven approach helps pharmaceutical marketing
teams to quickly plan, measure, validate, and optimize their sales and
marketing performance. Eularis offers pre-launch analytics, marketing mix
modeling, portfolio optimization, sales force effectiveness, managed care
analytics, and patient compliance solutions. Eularis has developed
significant experience in the global pharmaceutical market through client
engagements with AstraZeneca, GlaxoSmithKline, Merck, Pfizer and many others.
For more information about Eularis, visit http://www.eularis.com.
This release was issued on behalf of the above organization by
Send2Press(R), a unit of Neotrope(R). http://www.Send2Press.com
SOURCE Eularis
Tracey Haefele of Eularis, +1-646-673-8408, THaefele@eularis.com
